Skip to main content
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

HTAs published by Scottish Health Technology Group in the second quarter of 2021

03 Sep 2021

The Scottish Health Technologies Group (SHTG) is a national health technology assessment (HTA) agency providing advice to NHSScotland on the use of new and existing health technologies (excluding medicines), likely to have a significant impact on healthcare. NHSScotland is required to consider SHTG advice.

In the second quarter of 2021, SHTG published only one assessment on detection of paroxysmal atrial fibrillation in patients with newly diagnosed ischaemic stroke.

The key research question was the most clinically and cost-effective strategy to detect paroxysmal atrial fibrillation (PAF) in patients with newly diagnosed ischaemic stroke who are selected to have prolonged electrocardiogram (ECG) monitoring. One of the additional questions was comparative clinical and cost-effectiveness of ambulatory ECG monitoring technologies (Holter, event recorder, patch technologies) in the detection of PAF in patients with newly diagnosed ischaemic stroke selected to have prolonged ECG monitoring.

It was stated that there is insufficient evidence to make clear conclusions on the comparative clinical and cost-effectiveness of ambulatory ECG monitoring technologies. Drawing conclusions is challenging as the technology in this area is rapidly evolving. For patch technologies, the existing evidence is inconclusive and requires validation in larger diagnostic studies. NICE medical technologies guidance states that patch technology Zio XT is recommended (with caveats) as an option for people with suspected cardiac arrhythmias who would benefit from ambulatory ECG monitoring for longer than 24 hours. Evidence from randomized controlled trials comparing electronic loop recorders (ELRs) and ambulatory Holters in people with cryptogenic stroke is insufficient to distinguish the relative clinical effectiveness of the different devices.

There is insufficient evidence to define the optimal duration of long-term monitoring. Advice from Canada (CADTH, 2016) recommended seven days of continuous ambulatory cardiac monitoring with either a Holter monitor or external loop recorder for patients who have been discharged from the hospital after a stroke or TIA and who did not undergo continuous cardiac monitoring while in hospital.

The National Planning atrial fibrillation group will consider this SHTG assessment to inform more consistent practice across health boards.

See the full details in English here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).